Rithim Biologics®, Inc. is excited to announce the award of a National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI) fast track grant with a total value of $2.3M dependent on achieved milestones. Titled “Novel Gene Therapy, Techniques, and Devices to Prevent Ventricular Tachycardia”, the grant will support development of the company’s minimally invasive DAAViS™ catheter system, US patent 11,369,773 B2, to deliver gene therapies onto the ventricular surfaces of the human heart and a gene therapy to prevent the unique elements of the heart’s electrical circuit from causing ventricular tachycardia thereby eliminating these arrhythmias. The first period of the grant will begin immediately supported by over $300,000 to focused on catheter refinements.
“We are thrilled to have the University of Massachusetts Chan Medical School as a sub-awardee on this grant and look forward again to be working with this excellent institution,”, stated Ronald Anderson, President, CEO of Rithim Biologics and Principal Investigator on the grant.
For additional information contact:
Ronald L. Anderson, randerson@rithimbiologics.com
